Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc. · Investor Relations

Track ABCL — free

Use ABCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.74 -0.17 (-1.22%) At close · Oct 2
Rebalance outlook locked
Market Cap
$3.94B
Shares
306.61M
Volume · Oct 2 3.71M Avg daily vol (3M) 6.75M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-09 20:00 UTC AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 Earnings call

Recent news

Date Headline
2026-10-01 AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
2026-09-16 AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
2026-09-02 AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
2026-08-13 AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-08-11 AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-08-10 AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
2026-08-07 AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
2026-08-05 AbCellera Reports Q2 2026 Business Results
2026-07-29 AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
2026-07-07 AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-06 AbCellera Appoints Dr. Lynn Seely to its Board of Directors
2026-06-17 Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
2026-06-05 AbCellera Appoints Dr. Victor Sandor to its Board of Directors
2026-05-11 AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
2026-05-07 AbCellera to Present at Upcoming Investor Conferences in May and June 2026
2026-04-20 AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
2026-04-01 AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
2026-02-24 AbCellera Reports Full Year 2025 Business Results
2026-02-11 AbCellera to Present at Upcoming Investor Conferences in March and April 2026
2026-01-22 AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
2026-01-12 AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
2025-12-18 AbCellera and Bruker Reach Global Settlement of Patent Litigation

Past events

Date Event Type
2026-09-09 Cantor Global Healthcare Conference Conference
2026-08-10 AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Earnings call
2026-08-05 AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 Earnings call
2026-06-04 Jefferies Global Healthcare Conference in New York Conference
2026-05-14 Bank of America Health Care Conference Conference
2026-05-11 Q1 2026 Earnings Results and Business Update Earnings call
2026-04-21 2026 Bloom Burton & Co. Healthcare Investor Conference Conference
2026-03-17 KeyBanc Capital Markets Healthcare Forum Event
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2026-02-24 FY 2025 Earnings Results and Business Update Earnings call
2026-01-14 44th Annual JP Morgan Healthcare Conference Conference
2025-12-03 Piper Sandler Healthcare Conference Conference
2025-11-20 Jefferies Global Healthcare Conference Conference
2025-11-13 Stifel Healthcare Conference Conference
2025-11-06 Q3 2025 Earnings Results and Business Update Earnings call
2025-11-06 Truist Securities BioPharma Symposium Event
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference
2025-09-05 2025 Wells Fargo Healthcare Conference Conference
2025-08-07 Q2 2025 Earnings Results and Business Update Earnings call
2025-06-09 Goldman Sachs 46th Annual Global Healthcare Conference Conference
2025-05-08 Q1 2025 Earnings Results and Business Update Earnings call
2025-05-05 2025 Bloom Burton & Co. Healthcare Investor Conference Conference
2025-03-19 KeyBanc Capital Markets Healthcare Forum Event
2025-03-03 45th Annual TD Cowen Health Care Conference Conference
2025-02-27 FY 2024 Earnings Results and Business Update Earnings call

Source: https://investors.abcellera.com/overview/default.aspx

Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 1 filings 1 filers Visit website Investor relations